

Table S2. Therapeutic interventions of HFNC and MV groups

Interventions	HFNC, n(%)	MV,n(%)	<i>p</i> -value
Favipiravir			
Favipiravir	0 (0%)	1 (4.2%)	0.407
Favipiravir+Heparin+Dexamethasone	2 (5.7%)	2 (8.3%)	1.000
Favipiravir+Heparin+Dexamethasone+Steroid pulse	1 (2.9%)	0 (0%)	1.000
Remdesivir			
Remdesivir+Heparin+Dexamethasone	10 (28.6%)	3 (12.5%)	0.143
Remdesivir+Heparin+Dexamethasone+Baricitinib	7 (20.0%)	7 (29.2%)	0.416
Remdesivir+Heparin+Dexamethasone+Steroid pulse	1 (2.9%)	0 (0%)	1.000
Remdesivir+Heparin+Dexamethasone+Tocilizumab	5 (14.3%)	7 (29.2%)	0.198
Remdesivir+Heparin+Dexamethasone+Steroid pulse+Baricitinib	1 (2.9%)	0 (0%)	1.000
Remdesivir+Heparin+Steroid pulse	0 (0%)	1 (4.2%)	0.407
Favipiravir+Remdesivir			
Favipiravir+Remdesivir+Heparin+Dexamethasone	6 (17.1%)	3 (12.5%)	0.725
Favipiravir+Remdesivir+Heparin +Dexamethasone+Tcilizumab	1 (2.9%)	0 (0%)	1.000
Favipiravir+Remdesivir+Heparin +Dexamethasone+Baricitinib	1 (2.9%)	0 (0%)	1.000

HFNC, high flow nasal cannula; MV, mechanical ventilation.